Pharming Group (NASDAQ:PHAR – Get Free Report)’s share price shot up 5.4% during mid-day trading on Tuesday . The stock traded as high as $9.25 and last traded at $9.59. 2,252 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 5,358 shares. The stock had previously closed at $9.10.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on PHAR shares. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th. Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Jefferies Financial Group began coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.
View Our Latest Stock Analysis on PHAR
Pharming Group Stock Up 5.8 %
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group (NASDAQ:PHAR – Free Report) by 75.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is owned by hedge funds and other institutional investors.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
- Five stocks we like better than Pharming Group
- Compound Interest and Why It Matters When Investing
- What Does the Future Hold for Eli Lilly?
- Why is the Ex-Dividend Date Significant to Investors?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
- What is Forex and How Does it Work?
- 3 Consumer Stocks Call Option Traders Are Betting Big On
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.